The LEAD March newsletter has been posted. View it online here. Subscribe to the newsletter here.
LEAD March Newsletter Now Available
Category: Uncategorized
LEAD Responds to National Institute on Aging Request for Information About Improving Alzheimer’s Disease Clinical Trials
LEAD Coalition Executive Director Ian Kremer wrote to the National Institute on Aging to propose a range of specific actions and to call for genuine, candid, persistent, inclusive collaboration by all stakeholders. Read more…
LEAD Coalition Recommends Improvements to the National Alzheimer’s Plan
As U.S. Health and Human Services Secretary Sebelius develops the annual update for the National Plan to Address Alzheimer’s Disease, 54 LEAD Coalition member and partner organizations have joined together to offer recommendations for strengthening the Plan.
LEAD February Newsletter Now Available
The LEAD February newsletter has been posted. View it online here. Subscribe to the newsletter here.
Audio Recording: IRB Call, February 7, 2013
Accelerating Alzheimer’s Research & Drug Discovery Through a National Institutional Review Board for Neurodegenerative Diseases.
Forty-four LEAD Coalition Member and Partner Organizations Urge Congress to Protect Vital Alzheimer’s Disease Programs from the Sequester
LEAD is rallying a diverse and growing national coalition insisting that Congress do more, not less, to stand up for Americans facing Alzheimer’s disease and related disorders.
LEAD January Newsletter Now Available
The LEAD January Newsletter has been posted. View it online here. Subscribe to the newsletter here.
LEAD December Newsletter Now Available
The LEAD December Newsletter has been posted. View it online here. Subscribe to the newsletter here.
LEAD November Newsletter Now Available
The LEAD November Newsletter has been posted. View it online here. Subscribe to the newsletter here.
Twenty LEAD Member and Partner Organizations Urge the Food and Drug Administration to Prioritize Alzheimer’s Disease and Related Disorders
Twenty LEAD Coalition member and partner organizations have joined in a public comment to the Food and Drug Administration regarding implementation of PDUFA V patient-focused drug development activities. Read letter (PDF)